Can pancreatic Cancer's inflammatory footprint be stopped?

NCT ID NCT07765316

Not yet recruiting Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This observational study looks at how pancreatic cancer changes immune cells in the blood. Researchers will compare blood samples from 50 people with newly diagnosed, untreated pancreatic cancer to 50 age-matched people with a non-cancerous pancreatic condition. They aim to identify specific immune cell changes driven by tumor-related inflammation, which could reveal new targets for future treatments. Participants with cancer will be followed for 12 months to see if these immune changes relate to their clinical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could identify new drug targets to block cancer-related inflammation and potentially improve future treatments for pancreatic cancer.
What could go wrong: This is an observational study, so it won't test any treatment directly. Findings may not lead to immediate therapies, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreas disorder pancreatic ductal adenocarcinoma pancreatic intraductal papillary-mucinous neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DISEASES

More trials for these conditions

Other studies related to the condition(s) this trial covers.